TherapeuticsMD (TXMD) Gross Margin (2011 - 2023)

TherapeuticsMD (TXMD) has reported Gross Margin for 13 consecutive years, with 100.0% the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Gross Margin changed 0.0% year-over-year to 100.0%; the trailing twelve-month figure through Dec 2023 stood at 92.47% (down 2622.0% YoY), and the FY2023 full-year result was 100.0%, up 200.0% from the prior year.
• Gross Margin advanced to 100.0% in Q4 2023 per TXMD's latest filing, from 100.0% in the prior quarter.
• Across five years, Gross Margin topped out at 2082.45% in Q1 2022 and bottomed at 100.0% in Q3 2023.
• Historically, Gross Margin has averaged 184.76% across 5 years, with a median of 81.28% in 2019.
• The sharpest annual moves came in 2022 and 2023: Gross Margin jumped 200604 bps in 2022, then slumped 198245 bps in 2023.
• Over 5 years, Gross Margin stood at 81.9% in 2019, then retreated by 8 bps to 75.28% in 2020, then declined by 1 bps to 74.64% in 2021, then jumped by 34 bps to 100.0% in 2022, then changed by 0 bps to 100.0% in 2023.
• According to Business Quant data, Gross Margin over the past three periods registered 100.0%, 100.0%, and 100.0% for Q4 2023, Q3 2023, and Q2 2023 respectively.